Clofarabine in Chronic Lymphocytic Leukemia

Completed · Phase 1

Conditions studied: Hematologic Neoplasms, Lymphoproliferative Disorders, Leukemia, Leukemia, Lymphocytic, Chronic

In brief

This is a dose-escalation study to determine the maximum tolerated dose and toxic effects of clofarabine in patients with chronic lymphocytic leukemia and other acute leukemias. Clofarabine is a synthesized hybrid nucleoside analog, which is believed to possess the better qualities of fludarabine and chlorodeoxyadenosine, the 2 most active agents against lymphoproliferative disorders. Thus, it is hoped that this drug will be more active and less toxic than similar drugs.

Key facts

Study ID

NCT00028418

Run by

M.D. Anderson Cancer Center

People needed

100

Starts

1999-02-01

Expected to finish

2004-03-01

Last updated by the study team

2015-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of chronic lymphocytic leukemia
• Diagnosis of other acute leukemia
• At least 2 weeks since prior chemotherapy, immunotherapy, and/or radiotherapy
• Recovered from toxic effects of prior therapy
• Bilirubin no greater than 2 mg/dL
• Creatinine no greater than 1.5 mg/dL

You may not qualify if…

• Candidate for treatment of higher efficacy or priority
• Pregnant or nursing

Where it is running

• University of Texas M. D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.